A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months
Launched by IPSEN · Sep 10, 2013
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with DIE and having received surgery treatment within one month before inclusion
- • Premenopausal women aged \>=18 years old.
- • Written ICF has been obtained prior to any study-related procedures
- • Patient for whom the treating physician already made the decision to treat by Diphereline.
- • Patient should be mentally and physically able to express her symptom complaints and answer questions.
- Exclusion Criteria:
- • Pregnancy or lactation.
- • Patients currently on treatment or who have been on therapy with a GnRHa in the last 6 months.
- • Premenopausal women who may reach menopause within the 3 years post randomisation.
- • Hypersensitivity to Triptorelin or one of the excipients of Triptorelin 3.75mg
- • Treatment with another research drug over the last 3 months before the study
- • Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, , China
Beijing, , China
Beijing, , China
Chongqing, , China
Chongqing, , China
Hangzhou, , China
Hefei, , China
Nanchang, , China
Nanjing, , China
Shanghai, , China
Shanghai, , China
Shanghai, , China
Shenzhen, , China
Taiyuan, , China
Wuhan, , China
Wuhan, , China
Zhengzhou, , China
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials